Mathematical models show one dose of Shanchol may be sufficient during epidemics

Shanchol, the cholera vaccine used in endemic countries, is given in two doses 6 weeks apart. But some patients may simply not return for a second dose. If the second dose is delayed by more than 6 weeks, the WHO says, the whole regimen has to be restarted. According to a researcher at the Johns Hopkins Bloomberg School of Public Health, a single dose of Shanchol may provide sufficient protection in an epidemic. Andrew Azman used mathematical models to determine "minimum relative single-dose efficacy," the point at which a single-dose cholera vaccine campaign could be equally or more effective than a two-dose campaign in hypothetical epidemics. His models were based on outbreaks in Guinea, Zimbabwe and Haiti. And while Azman and his colleagues found evidence that a single dose of Shantha's Shanchol might be sufficient, "substantial uncertainty about one-dose efficacy remains" and field studies in areas with periodic cholera outbreaks are a priority, the team wrote. More

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.